Press coverage about Merrimack Pharmaceuticals (NASDAQ:MACK) has been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 49.0766831377025 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

MACK has been the subject of a number of recent research reports. Robert W. Baird reaffirmed a “hold” rating and set a $15.00 price target on shares of Merrimack Pharmaceuticals in a research note on Friday, October 13th. Zacks Investment Research downgraded Merrimack Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th.

Merrimack Pharmaceuticals (MACK) traded up $0.57 on Wednesday, hitting $11.02. The stock had a trading volume of 161,583 shares, compared to its average volume of 137,337. Merrimack Pharmaceuticals has a 52 week low of $10.04 and a 52 week high of $39.90. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.35 and a quick ratio of 3.35. The stock has a market cap of $142.46, a P/E ratio of 0.32 and a beta of 1.74.

Merrimack Pharmaceuticals (NASDAQ:MACK) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.88) by $1.48. equities analysts forecast that Merrimack Pharmaceuticals will post -3.15 earnings per share for the current year.

WARNING: “Merrimack Pharmaceuticals (MACK) Receives Daily Media Sentiment Rating of 0.17” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.

Insider Buying and Selling by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with's FREE daily email newsletter.